Novel Biologics Will Get Suffixes (Or At Least One Did)

US FDA's approval of Ultragenyx's Mepsevii (vestronidase alfa-vjbk) marks first novel biologic with a suffix, but 10 months after release of the naming guidance how – and even how widely – FDA will implement the policy remains uncertain.

the word suffix on cubes

It took 10 months following the release of final guidance, but the US FDA has finally attached a four-letter suffix to the non-proprietary name of a novel biologic with the agency's approval of Ultragenyx Pharmaceutical Inc.'s Mepsevii (vestronidase alfa-vjbk).

The agency approved the recombinant version of the enzyme beta-glucuronidase Nov. 15 as an enzyme replacement therapy for treatment of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet